CN102159558B - 2-芳基丙酸和其衍生物以及包含所述化合物的药物组合物 - Google Patents

2-芳基丙酸和其衍生物以及包含所述化合物的药物组合物 Download PDF

Info

Publication number
CN102159558B
CN102159558B CN200980136860.5A CN200980136860A CN102159558B CN 102159558 B CN102159558 B CN 102159558B CN 200980136860 A CN200980136860 A CN 200980136860A CN 102159558 B CN102159558 B CN 102159558B
Authority
CN
China
Prior art keywords
amino
phenyl
trifluoromethyl
base
propionic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980136860.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102159558A (zh
Inventor
马尔塞洛·阿莱格雷蒂
安德烈亚·阿拉米尼
詹卢卡·比安基尼
玛丽亚·坎迪达·切斯塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe SpA
Original Assignee
Dompe SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe SpA filed Critical Dompe SpA
Publication of CN102159558A publication Critical patent/CN102159558A/zh
Application granted granted Critical
Publication of CN102159558B publication Critical patent/CN102159558B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN200980136860.5A 2008-09-18 2009-09-18 2-芳基丙酸和其衍生物以及包含所述化合物的药物组合物 Active CN102159558B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08164605.1 2008-09-18
EP08164605A EP2166006A1 (en) 2008-09-18 2008-09-18 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
PCT/EP2009/062109 WO2010031835A2 (en) 2008-09-18 2009-09-18 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
CN102159558A CN102159558A (zh) 2011-08-17
CN102159558B true CN102159558B (zh) 2015-01-07

Family

ID=40291117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980136860.5A Active CN102159558B (zh) 2008-09-18 2009-09-18 2-芳基丙酸和其衍生物以及包含所述化合物的药物组合物

Country Status (17)

Country Link
US (1) US8624036B2 (enExample)
EP (2) EP2166006A1 (enExample)
JP (1) JP5571669B2 (enExample)
CN (1) CN102159558B (enExample)
AU (1) AU2009294558B2 (enExample)
CA (1) CA2737099C (enExample)
CY (1) CY1116176T1 (enExample)
DK (1) DK2346841T3 (enExample)
ES (1) ES2534634T3 (enExample)
HR (1) HRP20150395T1 (enExample)
IL (1) IL211683A (enExample)
PL (1) PL2346841T3 (enExample)
PT (1) PT2346841E (enExample)
RU (1) RU2520212C2 (enExample)
SI (1) SI2346841T1 (enExample)
SM (1) SMT201500098B (enExample)
WO (1) WO2010031835A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2634185T3 (pl) 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
KR102191084B1 (ko) * 2013-09-03 2020-12-15 사름 리미티드 약제학적 화합물
AR103399A1 (es) * 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
EP3117835A1 (en) * 2015-07-14 2017-01-18 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment of certain urological disorders
SG11201804484YA (en) 2016-01-15 2018-07-30 Dompe Farm Spa Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP3192504A1 (en) 2016-01-15 2017-07-19 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
US11291641B2 (en) 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3342407A1 (en) * 2017-01-03 2018-07-04 Dompé farmaceutici S.p.A. Il-8 inihibitors for use in the treatment of some urological disorders
EP3409277A1 (en) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
EP3868369A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
EP3868368A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
EP3884932A1 (en) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
CN115397404A (zh) 2020-03-26 2022-11-25 东佩制药股份公司 用于治疗covid-19的cxcl8抑制剂
EP4008325A1 (en) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use
WO2022098822A1 (en) 2020-11-05 2022-05-12 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (en) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4397305A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
EP4406942A1 (en) * 2023-01-26 2024-07-31 Dompe' Farmaceutici S.P.A. Stable monohydrate of df2755a and process for its preparation
EP4563594A1 (en) 2023-11-28 2025-06-04 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025528A (en) * 1973-10-24 1977-05-24 Shionogi & Co., Ltd. Thiazole derivatives of benzoic and phenylalkanoic acids
WO2003062215A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
CN1479715A (zh) * 2000-02-11 2004-03-03 ��ķ�ɷ����޹�˾ 用于抑制由白介素8诱导的中性粒细胞趋化作用的酰胺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1051906A (en) * 1973-10-24 1979-04-03 Shionogi And Co. Thiazole derivatives and production thereof
JPS5537556B2 (enExample) * 1973-12-27 1980-09-29
JPS565747B2 (enExample) * 1973-10-24 1981-02-06
JPS5629871B2 (enExample) * 1974-05-22 1981-07-10
JPS62142168A (ja) * 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
IT1298214B1 (it) 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
DE602005016937D1 (de) * 2004-03-23 2009-11-12 Dompe Pha R Ma Spa Res & Mfg Pharmazeutische zusammensetzung
HRP20161260T1 (hr) * 2005-11-24 2016-11-18 Dompé Farmaceutici S.P.A. Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže
AU2007253424B2 (en) * 2006-05-18 2013-03-07 Dompe' Farmaceutici S.P.A. (2R)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them
ES2394641T3 (es) * 2006-12-19 2013-02-04 Dompe' S.P.A. Ácidos 2-aril-2-fluoropropanoicos y derivados y composiciones farmacéuticas que los contienen
DE602008005488D1 (de) * 2007-10-18 2011-04-21 Dompe Spa (r)-4-(heteroaryl)phenylethylderivate und pharmazeutische zusammensetzungen damit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025528A (en) * 1973-10-24 1977-05-24 Shionogi & Co., Ltd. Thiazole derivatives of benzoic and phenylalkanoic acids
CN1479715A (zh) * 2000-02-11 2004-03-03 ��ķ�ɷ����޹�˾ 用于抑制由白介素8诱导的中性粒细胞趋化作用的酰胺
WO2003062215A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2

Also Published As

Publication number Publication date
BRPI0918759A2 (pt) 2015-12-29
EP2346841A2 (en) 2011-07-27
SMT201500098B (it) 2015-07-09
RU2520212C2 (ru) 2014-06-20
CA2737099A1 (en) 2010-03-25
EP2346841B1 (en) 2015-01-14
EP2166006A1 (en) 2010-03-24
WO2010031835A2 (en) 2010-03-25
AU2009294558A1 (en) 2010-03-25
JP5571669B2 (ja) 2014-08-13
CA2737099C (en) 2016-07-05
CN102159558A (zh) 2011-08-17
PT2346841E (pt) 2015-05-07
US20110207785A1 (en) 2011-08-25
JP2012502957A (ja) 2012-02-02
IL211683A0 (en) 2011-06-30
AU2009294558B2 (en) 2014-12-18
PL2346841T3 (pl) 2015-07-31
SI2346841T1 (sl) 2015-07-31
DK2346841T3 (en) 2015-04-20
IL211683A (en) 2014-01-30
CY1116176T1 (el) 2017-02-08
RU2011114992A (ru) 2012-10-27
WO2010031835A3 (en) 2010-06-24
ES2534634T3 (es) 2015-04-27
HRP20150395T1 (hr) 2015-06-19
US8624036B2 (en) 2014-01-07

Similar Documents

Publication Publication Date Title
CN102159558B (zh) 2-芳基丙酸和其衍生物以及包含所述化合物的药物组合物
AU2005223402B2 (en) 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them
PL207126B1 (pl) Zastosowanie enancjomerów (R) amidów kwasów 2-arylopropionowych i enancjomery (R) kwasów 2-arylopropionowych
JPWO2009072581A1 (ja) ラクタム化合物又はその塩及びｐｐａｒ活性化剤
US7868046B2 (en) (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them
RU2345063C2 (ru) Сульфоновые кислоты, производные указанных кислот и содержащие их фармацевтические композиции
RU2475486C2 (ru) (r)-4-(гетероарил)фенилэтильные производные и содержащие их фармацевтические композиции
JPWO2002044127A1 (ja) 置換カルボン酸誘導体
JP2004323504A (ja) ジベンジルアミン化合物及びその医薬用途
JP4795242B2 (ja) アミジン及びその誘導体並びにそれを含有する医薬組成物
JP4062204B2 (ja) ジヒドロナフタレン誘導体化合物およびその化合物を有効成分とする薬剤
CN1980908A (zh) 取代的噻唑乙酸作为crth2配体
JP2008528546A (ja) ２−アリールプロピオン酸誘導体の代謝産物及びそれを含有する医薬組成物
JPH0912554A (ja) フェノキシ酢酸誘導体及びこれを含有する医薬製剤
JPH068274B2 (ja) フェノキシ酢酸誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: DOMPE PHARMACEUTICAL S. P. A.

Free format text: FORMER OWNER: DOMPE SPA

Effective date: 20150902

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150902

Address after: Milan Italy

Patentee after: DOMPE SPA

Address before: Italy City

Patentee before: Dompe SPA